SiBone (NASDAQ:SIBN) Trading Down 3.9% - Time to Sell?

SiBone (NASDAQ:SIBN - Get Free Report)'s share price fell 3.9% during trading on Friday . The stock traded as low as $18.05 and last traded at $18.04. 4,414 shares were traded during trading, a decline of 99% from the average session volume of 392,073 shares. The stock had previously closed at $18.78.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SIBN. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SiBone in a report on Tuesday, May 6th. Truist Financial upped their price target on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th.

SiBone Trading Down 7.5%

The stock has a market cap of $740.31 million, a P/E ratio of -27.10 and a beta of 0.93. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.53 and a quick ratio of 7.26. The business's 50 day simple moving average is $18.17 and its 200 day simple moving average is $16.29.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. On average, analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Insider Activity at SiBone

In other news, SVP Michael A. Pisetsky sold 3,127 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $18.29, for a total transaction of $57,192.83. Following the completion of the sale, the senior vice president owned 261,681 shares of the company's stock, valued at approximately $4,786,145.49. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeffrey W. Dunn sold 3,377 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total transaction of $64,331.85. Following the completion of the sale, the director directly owned 17,354 shares of the company's stock, valued at approximately $330,593.70. This represents a 16.29% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 101,702 shares of company stock valued at $1,866,404. Insiders own 4.00% of the company's stock.

Institutional Trading of SiBone

A number of hedge funds and other institutional investors have recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone in the first quarter valued at approximately $34,000. Virtus Fund Advisers LLC acquired a new stake in shares of SiBone in the fourth quarter valued at approximately $40,000. GAMMA Investing LLC increased its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares in the last quarter. Virtus Advisers LLC acquired a new stake in SiBone during the 1st quarter worth $58,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in SiBone during the 4th quarter worth $97,000. Institutional investors and hedge funds own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.